Ibrutinib Is Effective In Refractory Type II Cryoglobulinemia

Publication date: Available online 3 September 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Shimoli V. Barot, Sarah S. Lee, Bhumika J. Patel, Jason N. ValentAbstractMonoclonal gammopathy of undetermined significance (MGUS) is an infrequent cause of type II mixed cryoglobulinemia (MC) yet these small B-cell clones can induce acute and profound end organ damage. Due to lack of explicit evaluation criteria, established standard of care and evidence-based guidelines, it continues to remain a diagnostic and therapeutic challenge. Here, we discuss our management approach to monoclonal gammopathy of renal significance (MGRS) related to MC and report the first case of the use of ibrutinib in a refractory setting that resulted in a complete and durable clinical response with reversal of kidney injury.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research

Related Links:

Abstract The development of chimeric antigen receptor (CAR) T-cell therapy for select hematological malignancies represents one of the most remarkable therapeutic advances in the past decade. Currently, CD19-targeted CAR T-cell therapy is approved for relapsed/refractory diffuse large B cell lymphoma and acute lymphoblastic leukemia. However, there is significant interest in the application of CAR T-cell therapy to other hematological malignancies, including multiple myeloma, where the current focus is on the development of B cell maturation antigen-directed CAR T-cell therapy. Despite the successes achieved to da...
Source: Clinical Lymphoma and Myeloma - Category: Cancer & Oncology Authors: Tags: Clin Pharmacol Ther Source Type: research
In conclusion, the triple combination of ATRA and ATO plus IDA as both an induction and consolidation therapy for the HR and SR groups attained excellent outcomes, and this regimen was effective, safe and easy, without maintenance therapy. The triple combination treatment might be a preferred frontline therapy for APL patients, especially for HR patients or patients with the APL FLT3-ITD mutation.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
CONCLUSIONThe majority of real-world RRMM patients were ineligible for hallmark RCTs. Eligibility rates varied across RCTs, underlining the flawed nature of cross-study comparisons without RCT validation. OS was significantly affected by inability to meet criteria highlighting limited generalizability of RCT results. Greater efforts should be made to broaden eligibility criteria to reflect real-world clinical characteristics to narrow the gap between RCT efficacy and observed effectiveness in real-world MM patients.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
ConclusionsFLT3 mutation was not common in Chinese ALL patients. Age of onset, platelet counts and transplant status rather than FLT3 mutations were independent prognostic variables for ALL cases on OS in our cohort. In spite of small sample size, ETP-ALL may indicate a comparable higher FLT3-mutant rate. Since ETP-ALL has been identified as high-risk subgroup, these data warrant clinical studies with the implementation of FLT3 inhibitors in addition to early allogeneic hematopoietic stem cell transplantation for FLT3 mutant ETP-ALL.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 30 September 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Guillaume Richard-Carpentier, Elias Jabbour, Nicholas J. Short, Caitlin R. Rausch, Jonathan M. Savoy, Prithviraj Bose, Musa Yilmaz, Nitin Jain, Gautam Borthakur, Maro Ohanian, Yesid Alvarado, Michael Rytting, Partow Kebriaei, Marina Konopleva, Hagop Kantarjian, Farhad RavandiAbstractBackgroundPatients with relapsed or refractory (R/R) T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) have dismal outcomes. Preclinical studies suggest that T-ALL cells are sensitive to BCL2 inhibition. Clinical activity of venetocla...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 30 September 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Marta Sobas, Anna Czyż, Pau Montesinos, Anna Armatys, Grzegorz Helbig, Aleksandra Holowiecka, Agnieszka Pluta, Ewa Zarzycka, Beata Piątkowska-Jakubas, Maciej Majcherek, Krzysztof Lewandowski, Aleksandra Gołos, Monika Paluszewska, Monika Podhorecka, Jolanta Oleksiuk, Anna Skręt, Dorota Hawrylecka, Renata Ewa Guzicka-Kazimierczak, Marzena Wątek, Tomasz GromekAbstractAcute promyelocytic leukemia (APL) has a favorable prognosis. However, results of randomized studies not necessarily reflect the outcomes of real-lif...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
ConclusionsPatients with hematological malignancy infected by A. sobria that either is  ≥ 65-years-old does not have a disease remission or develop shock, the risk of dying increases. The physicians can use our results to guide the prognosis of patients infected by this bacteria.Legal entity responsible for the studyThe authors.FundingHas not received any funding.DisclosureAll authors have declared no conflicts of interest.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
Activating mutations in FLT3 are frequent in acute myeloid leukemia (AML) and have important prognostic and therapeutic implications. Meanwhile, FLT3 aberrations have been detected in a smaller fraction of acute lymphoblastic leukemia (ALL), and their prognostic value are not well established. Therefore, we assessed the FLT3 mutation in Chinese adolescent and adult ALL patients.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
The bone marrow (BM) microenvironment allows for migration, growth, proliferation, and drug-resistant clonal evolution of multiple myeloma (MM) cells. BM adipocytes (BMAs) expand with aging and obesity, two key MM risk factors. BMAs are important contributors to systemic adipokine levels, bone health and hematopoiesis, and have also recently been implicated in acute myeloid leukemia. We investigated the interactions between MM cells and BMAs and found that adipocyte gene expression and cytokine secretion profiles are altered, creating a "MM-associated ” adipocyte (MM-adipocyte) phenotype that is supportive of MM cell survival.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research
Rapid remission has long been recognized as an important predictor for long-time survival in acute leukemia (AL). However, the effects of response kinetics on survival seems to be different from those in AL. A rapid reduction of tumor burden probably indicates a chemotherapy-sensitive population. But on the other hand, a high proliferative activity of plasma cell may be responsible for the rapid response. The effects of response kinetics on outcome for MM remain largely unexplored. Method: The relationship between response kinetics and outcome were prospectively assessed in 626 patients with newly diagnosed MM that were in...
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research
More News: Acute Leukemia | Cancer & Oncology | Leukemia | Lymphoma | Myeloma | Urology & Nephrology